Journal Paper

Paper Information

Journal:
Year:0 | Volume: | Issue:
Start Page: | End Page:

video

sound

Persian Version

View:

16,072

Download:

6,622

Cites:

Information Journal Paper

Title

INTRAVITREAL EXPANSILE GAS AND BEVACIZUMAB INJECTION FOR SUBMACULAR HEMORRHAGE DUE TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Writers

NOURINIA R. | JABARPOUR BONIAADI MOHAMMAD HOSSEIN | AHMADIEH H.

Pages

 Start Page 168 | End Page 174

Abstract

 Purpose: To evaluate the results of intravitreal expansile gas injection, with or without recombinant tissue plasminogen activator (rtPA), followed by intravitreal BEVACIZUMAB injection for treatment of SUBMACULAR HEMORRHAGE (SMH) secondary to neovascular age-related MACULAR DEGENERATION (AMD).Methods: In this interventional case series, 5 eyes of 5 patients with SMH secondary to choroidal neovascularization (CNV) due to neovascular AMD were treated with 0.3 cc intravitreal SF6 (and 50 mg of rtPA in two eyes), followed by face-down positioning; 24 hours later, 1.25 mg of BEVACIZUMAB was injected intravitreally. Main outcome measures included displacement of SMH and best corrected visual acuity (BCVA).Results: Mean patient age was 75.6±9.2 (range, 60-83) years, mean duration of symptoms was 6.4±3.2 (range, 3-10) days, and mean number of BEVACIZUMAB injections was 1.8 (range, 1-3). Mean preoperative BCVA was 1.28±0.27 logMAR which improved significantly to 0.57±0.33 logMAR at 12 months (P=0.042). SMH displacement occurred in all eyes, and visual acuity improved and remained stable during the follow-up period of 12 months.Conclusion: Intravitreal expansile gas injection, with or without rtPA, followed by intravitreal BEVACIZUMAB injection, seems to be an effective modality for SMH displacement and treatment of the underlying CNV in neovascular AMD.

Cites

  • No record.
  • References

  • No record.
  • Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops